Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137129 | 0.79 | MGLL (0.63) | MGLLALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL20168791 | 0.73 | MGLL (0.47) | MGLLPTGDR2 | |
| SCHEMBL29561155 | 0.70 | MGLL (0.77) | MGLLALDH1A1KDM4EPOLB | |
| SCHEMBL20137101 | 0.70 | MGLL (0.77) | MGLLALDH1A1KDM4EPOLB | |
| SCHEMBL20137094 | 0.70 | MGLL (0.66) | MGLLALDH1A1NPSR1KDM4ETDP1 | |
| SCHEMBL29562063 | 0.70 | MGLL (0.66) | MGLLALDH1A1NPSR1KDM4ETDP1 | |
| SCHEMBL28712188 | 0.67 | MGLL (0.49) | MGLLALDH1A1MAPK1NPSR1KDM4E | |
| SCHEMBL20151787 | 0.67 | MGLL (0.85) | MGLL | |
| SCHEMBL28518232 | 0.66 | KDM4E (0.34) | ALDH1A1MAPK1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL3773661 | 0.66 | AGTR2 (0.50) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885ALDH1A1 4349/4885MAPK1 2543/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885ALDH1A1 4349/4885MAPK1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.